HOME >> MEDICINE >> NEWS
New study shows patients more willing to consider self-injectable HIV therapy than many physicians anticipate

Initial results from the OpenMind study, the largest behavioural study to look at both patients' and physicians' perceptions of HIV care in treatment-experienced patients, were revealed today at EACS. The study's findings are anticipated to help physicians implement improved care to HIV patients and help pave the way for better acceptance and integration of other new innovative drugs such as monoclonal antibodies that are increasingly being developed for the management of HIV and other diseases.

The study was conceived to look at attitudes to FUZEON (enfuvirtide), the first approved HIV fusion inhibitor, and an important option for treatment-experienced patients who face HIV resistance. FUZEON presents unique challenges because it is the first self-injectable antiretroviral whereas all other treatments are oral.

Highlights from today's data show that:

  • Patients are more willing to consider and use self-injectable therapy than many physicians anticipate
  • Three-quarters (76%) of patients would consider using a self-injectable HIV therapy if their physician recommended it
  • Worryingly, only one quarter (28%) of patients who are potentially eligible for FUZEON had actually discussed this injectable option with their physicians
  • Only 10% of eligible patients were currently prescribed FUZEON, despite the fact that it is recommended in key international HIV treatment guidelines

This study also identifies some of the main reasons why many physicians may be reluctant to prescribe a treatment of proven efficacy and safety. The reasons include; the physicians' perception that patients would be reluctant to use a self-injectable therapy, the physicians' opinion that the patient would not be able to incorporate FUZEON into their lifestyle and the potential misconception that FUZEON is not appropriately recommended in guidelines.

"Physicians' best intentions in trying to match treatments t
'"/>

Contact: Kate Pogson
kate.pogson@ketchum.com
44-207-611-3552
Ketchum
18-Nov-2005


Page: 1 2

Related medicine news :

1. Childhood obesity indicates greater risk of school absenteeism, Penn study reveals
2. Penn study finds pro-death proteins required to regulate healthy immune function
3. New study shows promise in reducing surgical risks associated with surgical bleeding
4. New study counts the economic cost of persistent pain in Australia
5. UCLA researchers awarded $9M contract for study identifiying antibiotic treatment for MRSA
6. Most seniors now have drug coverage, U-M study shows
7. To gain muscle and lose fat, drink milk: study
8. Wheres the beef? Not enough of it is on elders plates, muscle-metabolism study suggests
9. Even older women at high risk have little interest in being tested for HIV, study finds
10. Metabolic study in mice could lead to good cholesterol boosters
11. Michigan-CDC study supports value of social restrictions during influenza pandemics

Post Your Comments:
(Date:3/31/2015)... NC (PRWEB) March 31, 2015 Smartlink ... engagement technology, today announced that Chris Lynch, Managing ... Annual Southeast Venture Conference (SEVC) this week in Charlotte, ... technology firms in the southeast region and provides these ... capitalists and private equity investors. , This year’s ...
(Date:3/31/2015)... 2015 These two automakers will address ... ecosystem. They will highlight a shift that has become ... insurance a business proposition for the insurance carriers alone. ... the opportunities that lie in store for them. ... automakers are now alive to their own involvement in ...
(Date:3/31/2015)... MA and Willimantic, CT (PRWEB) March 31, 2015 ... the word about the settlement of a nationwide ... No. 5:11-CV-17, District of Vermont) and seeking to ... to patients who did not meet an “improvement ... Medicare Advocacy are releasing a video conversation with ...
(Date:3/31/2015)... 2015 April is Parkinson’s disease Awareness Month ... announce 30 Days, 30 Ways to Make a Difference. ... that will offer a new action each day throughout April ... who battle this disease. , Every nine minutes ... alone nearly 5,000 individuals in this country will learn they ...
(Date:3/31/2015)... Azilen Technologies adds yet another ... Development Company’ award at GESIA 2015. The firm earned ... Annual Award GESIA 2015. This marks Azilen’s second triumph ... It previously won the ‘Best Product Innovation’ award at ... product development, enterprise mobility solutions and open source technologies. ...
Breaking Medicine News(10 mins):Health News:Smartlink Mobile Chosen to Present at Southeast Venture Conference 2Health News:TU-Automotive: Fiat and Renault-Nissan at the Centre of a Motor Insurance Evolution 2Health News:Mythbusters: Harmony Healthcare International and Center for Medicare Advocacy Team-Up to Dispel Myths On Medicare Coverage for Maintaining a Patient’s Condition 2Health News:Mythbusters: Harmony Healthcare International and Center for Medicare Advocacy Team-Up to Dispel Myths On Medicare Coverage for Maintaining a Patient’s Condition 3Health News:Mythbusters: Harmony Healthcare International and Center for Medicare Advocacy Team-Up to Dispel Myths On Medicare Coverage for Maintaining a Patient’s Condition 4Health News:Join The American Parkinson Disease Association to Commemorate April Parkinson's Awareness Month 2Health News:Join The American Parkinson Disease Association to Commemorate April Parkinson's Awareness Month 3Health News:Azilen Technologies Receives ‘Best Product Development Company’ Award at GESIA 2015 2
(Date:3/31/2015)... 31, 2015 /CNW/ - T-Bird Pharma Inc. (TSXV:TPI) ("T-Bird" or ... quality medical marijuana products and a licensed producer ("LP") ... Regulations ( Canada ) ("MMPR"), is pleased ... Corporation of the District of Saanich ... premises which now allows for commercial distribution of medical ...
(Date:3/31/2015)... 31, 2015 ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ... Hydrochloride 150mg, 225mg and 300mg oral tablets, indicated for ... US market for Propafenone Hydrochloride 150mg, 225mg and 300mg ... Arthur S. Przybyl , President and ... the launch of our fourth product from the portfolio ...
(Date:3/31/2015)... DUBLIN , Mar. 27, 2015 Research ... announced the addition of the "European Laboratory ... Information System), by Type (Clinical Pathology Laboratory Information ... to 2019" report to their offering. ... estimated to grow at a CAGR of 7.6% ...
Breaking Medicine Technology:T-Bird Pharma Inc. Announces Final Municipal Rezoning Approval 2T-Bird Pharma Inc. Announces Final Municipal Rezoning Approval 3ANI Pharmaceuticals Announces the Launch of Propafenone Tablets 2ANI Pharmaceuticals Announces the Launch of Propafenone Tablets 3European Laboratory Information System Market Report 2015: Germany holds a larger share of the laboratory information systems market 2European Laboratory Information System Market Report 2015: Germany holds a larger share of the laboratory information systems market 3
Cached News: